Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
by Zacks Equity Research
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Conatus (CNAT) Completes Enrollment in Phase II NASH Study
by Zacks Equity Research
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
Bristol-Myers' Sprycel Gets European Nod for Label Expansion
by Zacks Equity Research
Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
Stock Market News For Feb 12, 2019
by Zacks Equity Research
Markets closed mostly higher on Monday as fresh rounds of trade talks between the United States and China began.
Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake
by Zacks Equity Research
Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Dow 30 Stock Roundup: Disney Earnings Impress, Pfizer's Cancer Drug Gets CHMP Nod
by Swarup Gupta
The index endured a mixed week after trade war fears reemerged.
Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.
Winners & Losers from Trump's State of the Union Address
by Swarup Gupta
While pharma majors could face greater scrutiny on drug pricing, defense, infrastructure and energy are likely to emerge as big winners.
Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.
Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod
by Zacks Equity Research
Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets recommendation from CHMP of the EMA.
The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer
Dow 30 Stock Roundup: MCD, BA, 3M, MSFT, PFE, V Earnings Impress
by Swarup Gupta
The index enjoyed a strong week overall, bolstered by encouraging earnings.
Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY
by Zacks Equity Research
Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.
Top Analyst Reports for Boeing, Thermo Fisher & Anthem
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Thermo Fisher (TMO) and Anthem (ANTM).
Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status
by Zacks Equity Research
Merck's (MRK) investigational pneumococcal vaccine V114 gets FDA's Breakthrough Therapy designation for prevention of invasive pneumococcal disease.
Company News For Jan 30, 2019
by Zacks Equity Research
Companies In The News Are: HOG,XRX,PFE,HCA
Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study
by Zacks Equity Research
Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.
Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid
by Zacks Equity Research
Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.
Apple Earnings Preview & Latest Results from Verizon, 3M, and Pfizer
by Ryan McQueeney
Ryan McQueeney recaps earnings results from Verizon, 3M, Pfizer, and Harley-Davidson. Later, he previews the upcoming report of sputtering tech behemoth Apple.
Apple To Report Fiscal Q1 Earnings
by Zacks Equity Research
Apple To Report Fiscal Q1 Earnings
The Apple (AAPL) of Investors' Eye
by Mark Vickery
With Apple (AAPL) reporting fiscal Q1 earnings results after the closing bell this afternoon, this is where the majority of attention will be.
Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips
by Zacks Equity Research
Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.